Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 18, 2016, reports the release of earnings for the fourth calendar quarter of 2015 by Perrigo Company plc, an Ireland-based pharmaceutical company. The filing serves to notify the SEC of the earnings release attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the attached press release (Exhibit 99.1) for these figures. The document details the methodology for non-GAAP financial measures, noting that the Company provides reconciliations for net sales, gross profit, operating income, net income, and earnings per share to exclude specific non-core items.
Material Changes and Non-GAAP Adjustments
The Company excludes various items from reported results to evaluate core business performance. Key exclusions for the fourth quarter of 2015 include:
- Amortization of acquired intangible assets.
- Restructuring charges related to acquisitions and organizational improvements.
- Intangible asset impairment charges and impairment charges on assets held for sale.
- Legal and consulting fees related to the defense against Mylan N.V.
- Acquisition and integration-related charges.
- Impairment on investment securities and equity method investment losses.
Similar exclusions were applied to the fourth quarter of 2014 and year-to-date periods, including financing charges, derivative losses, and litigation settlements.
Guidance, Outlook, and Risks
For the 2016 calendar year guidance, the Company plans to exclude amortization of acquired intangible assets, the impact of acquisitions on deferred tax balances, and integration and restructuring-related charges. A significant risk factor highlighted in the exclusions is the ongoing legal defense against Mylan N.V., which incurred specific legal and consulting fees in 2015.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP financial figures for Q4 2015.
- Verify the magnitude of the "Legal and consulting fees related to the Mylan defense" to assess litigation risk exposure.
- Examine the reconciliation tables in the press release to understand the impact of intangible asset impairments and goodwill impairments on reported earnings.
- Confirm the specific impact of the Mylan N.V. defense on the Company's liquidity and future cash flow projections.